ArticleCellular and molecular life sciences : CMLS2026
LC3-associated phagocytosis is a new strategy to inhibit picornavirus infection through increasing interferon levels and lysosomal degradation.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
LC3-associated phagocytosis (LAP) is a novel type of noncanonical autophagy that contributes to inflammatory responses and immune regulation in various cell and tissue types infected by DNA and RNA viruses. The role of LAP during picornavirus infection remains unclear. Here, using PK-15 cells, Vero cells and mice lacking the WD domain of ATG16L1 as a LAP deficient model, we found that infection with foot-and-mouth disease virus (FMDV), senecavirus A (SVA), and enterovirus 71 (EV71) induced LAP, and LAP inhibited the replication of these viruses. Further investigation revealed that LAP inhibited FMDV replication through increasing interferon levels and promoting lysosomal degradation. In addition, GBP1, IFITM3, OASL, IIFIT1, Mx1 and other innate immune factors related to the interferon pathway were significantly inhibited in LAP-deficient cells during FMDV infection. Furthermore, LAP-deficient mice were more susceptible to FMDV, with greater lethality and more severe pathological damage and viral loads in the blood, heart, spleen, liver, lungs and kidneys. In conclusion, this study uncovers a novel mechanism of the host antiviral effect of LAP on picornaviruses and provides a theoretical basis for the development of new antiviral strategies against picornaviruses.Importance:FMDV, SVA and EV71 all belong to the Picornaviridae family, which has single-stranded positive-sense RNA, is nonenveloped and can cause diseases in both humans and animals. A noncanonical function of the autophagy machinery known as LC3-associated phagocytosis (LAP), utilizes a portion of components of the canonical autophagy machinery, is one of the important ways for cells to cope with pathogen infection. This study revealed a new strategy to inhibit picornavirus replication through increasing interferon levels and promoting lysosomal degradation, further highlighting the important role of LAP in antiviral immunity and providing a theoretical basis and experimental support for the development of new antiviral strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.